We are live on ! Find out more
ACM

ACT Capital Management Portfolio holdings

AUM $153M
This Fund
S&P 500
This Quarter Est. Return
+9.63%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$193M
AUM Growth
-$1.65M
Cap. Flow
+$718
Cap. Flow %
0%
Top 10 Hldgs %
60.41%
Holding
141
New
23
Increased
22
Reduced
12
Closed
32

Top Buys

Rank Stock Value
1
INMB icon
INmune Bio
INMB
+$5.31M
2
STAA icon
STAAR Surgical
STAA
+$5.12M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$2.44M
4
NVNO
enVVeno Medical
NVNO
+$1.94M
5
CVX icon
Chevron
CVX
+$1.6M

Top Sells

Rank Stock Value
1
FLNA
Filana Therapeutics
FLNA
+$3.85M
2
U icon
Unity
U
+$3.33M
3
SKIN icon
SkinHealth Systems
SKIN
+$2.9M
4
FFIV icon
F5
FFIV
+$2.71M
5
NVAX icon
Novavax
NVAX
+$2.19M

Sector Composition

Rank Sector Weight
1 Healthcare 78.61%
2 Financials 5.86%
3 Technology 3.93%
4 Communication Services 3.41%
5 Consumer Discretionary 1.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRIS icon
51
Curis
CRIS
$8.85M
$626K 0.32%
200
– –
APLT
52
DELISTED
Applied Therapeutics
APLT
$623K 0.32%
37,500
– –
CYPH
53
Cypherpunk Technologies Inc
CYPH
$78M
$622K 0.32%
15,500
+2,100
+16% +$39.5K
RETA
54
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$604K 0.31%
6,000
-6,600
-52% -$774K
CSBR icon
55
Champions Oncology
CSBR
$73.6M
$597K 0.31%
58,500
+8,500
+17% +$86.5K
SSYS icon
56
Stratasys
SSYS
$778M
$592K 0.31%
+27,500
New +$596K
COUP
57
DELISTED
Coupa Software Incorporated
COUP
$526K 0.27%
+2,400
New +$564K
AKRO
58
DELISTED
Akero Therapeutics
AKRO
$514K 0.27%
+23,000
New +$521K
DPRO
59
Draganfly
DPRO
$161M
$503K 0.26%
+6,000
New +$507K
KALA icon
60
KALA BIO
KALA
$13.6M
$498K 0.26%
76
– –
AMPE
61
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$484K 0.25%
972
– –
ADAP
62
DELISTED
Adaptimmune Therapeutics
ADAP
$465K 0.24%
+90,000
New +$404K
DKNG icon
63
DraftKings
DKNG
$10.8B
$462K 0.24%
+9,600
New +$509K
ZYME icon
64
Zymeworks
ZYME
$1.73B
$407K 0.21%
+14,000
New +$465K
RYTM icon
65
Rhythm Pharmaceuticals
RYTM
$7.59B
$405K 0.21%
31,000
– –
SIOX
66
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$401K 0.21%
185,000
– –
OYST
67
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$373K 0.19%
31,500
– –
AUD
68
DELISTED
Audacy, Inc.
AUD
$359K 0.19%
97,500
– –
ATNM icon
69
Actinium Pharmaceuticals
ATNM
$23.5M
$332K 0.17%
+37,500
New +$261K
SQZ
70
DELISTED
SQZ Biotechnologies Company
SQZ
$317K 0.16%
22,000
+14,500
+193% +$197K
ABEO icon
71
Abeona Therapeutics
ABEO
$388M
$311K 0.16%
+11,120
New +$356K
CTSO icon
72
Cytosorbents Corp
CTSO
$24.2M
$284K 0.15%
35,000
– –
F icon
73
Ford
F
$56.3B
$283K 0.15%
20,000
-32,000
-62% -$435K
GAMB
74
DELISTED
Gambling.com
GAMB
$274K 0.14%
+30,000
New +$262K
JMIA
75
Jumia Technologies
JMIA
$727M
$264K 0.14%
14,200
-300
-2% -$6.35K
1 2
3
4 5

Similar funds

BCI
Blue Capital Inc Omaha, Nebraska $153M AUM 28.69% 1-Year Est. Return
APW
Atlantic Private Wealth Chapel Hill, North Carolina $153M AUM 15.75% 1-Year Est. Return
DAM
Doheny Asset Management Los Angeles, California $153M AUM 42.04% 1-Year Est. Return
BVC
Bright Valley Capital Hong Kong $153M AUM 16.24% 1-Year Est. Return
RHAM
Round Hill Asset Management Pasadena, California $153M AUM 6.67% 1-Year Est. Return
RFN
Redwood Financial Network Solon, Ohio $153M AUM 17.17% 1-Year Est. Return
SGM
Sellaronda Global Management New York $152M AUM 2.1% 1-Year Est. Return
HWM
Horizons Wealth Management Asheville, North Carolina $152M AUM 9.43% 1-Year Est. Return

ACT Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, ACT Capital Management held 141 positions worth $193M, down 0.85% from $195M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

ACT Capital Management's Q3 2021 filing shows 23 new, 22 increased, 12 reduced and 32 closed positions. Its largest new stake was INmune Bio: 275,000 shares worth $5.34M. The largest sale was Filana Therapeutics, an estimated $3.85M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 80% a quarter earlier, followed by Financials and Technology.

  • ACT Capital Management's largest Q3 2021 buy was INmune Bio: 275,000 shares worth $5.34M.
  • ACT Capital Management added most to STAAR Surgical in Q3 2021, an estimated $5.12M increase.
  • ACT Capital Management's biggest Q3 2021 reduction was Unity, cutting an estimated $3.33M.
  • ACT Capital Management fully exited Filana Therapeutics in Q3 2021, selling an estimated $3.85M.
  • ACT Capital Management's ten largest holdings make up 60% of its $193M portfolio in Q3 2021.
  • ACT Capital Management opened 23 new positions and closed 32 in Q3 2021.
  • ACT Capital Management's portfolio value fell 0.85% quarter-over-quarter to $193M.

Based on ACT Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.